BR112022025012A2 - Inibidores de quinase de nek7 - Google Patents
Inibidores de quinase de nek7Info
- Publication number
- BR112022025012A2 BR112022025012A2 BR112022025012A BR112022025012A BR112022025012A2 BR 112022025012 A2 BR112022025012 A2 BR 112022025012A2 BR 112022025012 A BR112022025012 A BR 112022025012A BR 112022025012 A BR112022025012 A BR 112022025012A BR 112022025012 A2 BR112022025012 A2 BR 112022025012A2
- Authority
- BR
- Brazil
- Prior art keywords
- nek7
- compounds
- kinase inhibitors
- activity
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Epidemiology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063036244P | 2020-06-08 | 2020-06-08 | |
| US202163170776P | 2021-04-05 | 2021-04-05 | |
| US202163185257P | 2021-05-06 | 2021-05-06 | |
| PCT/US2021/036398 WO2021252488A1 (en) | 2020-06-08 | 2021-06-08 | Inhibitors of nek7 kinase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112022025012A2 true BR112022025012A2 (pt) | 2023-02-14 |
Family
ID=76731040
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112022025012A BR112022025012A2 (pt) | 2020-06-08 | 2021-06-08 | Inibidores de quinase de nek7 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230203045A1 (https=) |
| EP (1) | EP4161933A1 (https=) |
| JP (1) | JP2023528659A (https=) |
| KR (1) | KR20230035311A (https=) |
| CN (1) | CN116075513A (https=) |
| AU (1) | AU2021289345A1 (https=) |
| BR (1) | BR112022025012A2 (https=) |
| CA (1) | CA3186041A1 (https=) |
| CO (1) | CO2022019131A2 (https=) |
| IL (1) | IL298849A (https=) |
| MX (1) | MX2022015495A (https=) |
| TW (1) | TWI908811B (https=) |
| WO (1) | WO2021252488A1 (https=) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS65962B1 (sr) | 2020-05-08 | 2024-10-31 | Halia Therapeutics Inc | Inhibitori nek7 kinaze |
| US20240400551A1 (en) * | 2021-01-25 | 2024-12-05 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| US20240158394A1 (en) * | 2022-09-14 | 2024-05-16 | Halia Therapeutics, Inc. | Nek7 inhibitors |
| WO2025140570A1 (zh) * | 2023-12-29 | 2025-07-03 | 北京普祺医药科技股份有限公司 | 一种nek7抑制剂、药物组合物及其用途 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5052558A (en) | 1987-12-23 | 1991-10-01 | Entravision, Inc. | Packaged pharmaceutical product |
| US5033252A (en) | 1987-12-23 | 1991-07-23 | Entravision, Inc. | Method of packaging and sterilizing a pharmaceutical product |
| US5323907A (en) | 1992-06-23 | 1994-06-28 | Multi-Comp, Inc. | Child resistant package assembly for dispensing pharmaceutical medications |
| MXPA03008560A (es) | 2001-03-22 | 2004-06-30 | Abbot Gmbh & Co Kg | Pirazolopirimidinas como agentes terapeuticos. |
| US20110189167A1 (en) | 2007-04-20 | 2011-08-04 | Flynn Daniel L | Methods and Compositions for the Treatment of Myeloproliferative Diseases and other Proliferative Diseases |
| UY33288A (es) | 2010-03-25 | 2011-10-31 | Glaxosmithkline Llc | Derivados de indolina inhibidores de la proteina quinasa r del reticulo endoplasmatico |
| EP2802212B1 (en) | 2012-01-12 | 2015-12-30 | Basf Se | Herbicidal isoxazolo[5,4-b]pyridines |
| CN105017256A (zh) | 2014-04-29 | 2015-11-04 | 浙江导明医药科技有限公司 | 多氟化合物作为布鲁顿酪氨酸激酶抑制剂 |
| RU2724345C2 (ru) | 2015-10-09 | 2020-06-23 | Галапагос Нв | N-СУЛЬФОНИЛИРОВАННЫЕ ПИРАЗОЛО[3,4-b]ПИРИДИН-6-КАРБОКСАМИДЫ И СПОСОБ ИХ ПРИМЕНЕНИЯ |
| CN108250200A (zh) | 2016-12-28 | 2018-07-06 | 中国科学院上海药物研究所 | 一种具有Axl抑制活性的化合物及其制备和应用 |
| DE102017200543A1 (de) | 2017-01-13 | 2018-07-19 | Baden-Württemberg Stiftung Ggmbh | Verfahren zur Behandlung einer Oberfläche eines Hartmetallkörpers und zur Beschichtung des behandelten Hartmetallkörpers mit einer Diamantschicht |
| DE102017118230B4 (de) * | 2017-08-10 | 2021-04-22 | Christoph Lucks | Verfahren zur Analyse und/oder Überwachung von Brücken sowie entsprechendes System und entsprechende Verwendung |
| MX2020001776A (es) * | 2017-08-15 | 2020-03-24 | Inflazome Ltd | Sulfonilureas y sulfoniltioureas como inhibidores de nlrp3. |
| KR20200087759A (ko) | 2017-11-09 | 2020-07-21 | 인플라좀 리미티드 | 신규한 설폰아마이드 카복스아마이드 화합물 |
| IL277408B2 (en) * | 2018-04-05 | 2024-08-01 | Merck Patent Gmbh | Heteroaryl compounds as IRAK type II inhibitors and their use |
| AR118119A1 (es) | 2019-02-18 | 2021-09-22 | Genentech Inc | Compuestos de pirido-pirimidinilo y métodos de uso |
| CN111646995B (zh) * | 2019-03-04 | 2023-03-21 | 四川大学 | 4-氨基-嘧啶并氮杂环-苯基脲类衍生物及其制备方法和用途 |
| WO2021057877A1 (zh) * | 2019-09-26 | 2021-04-01 | 深圳市塔吉瑞生物医药有限公司 | 取代的芳香稠合环衍生物及其组合物及用途 |
| AU2020436612A1 (en) * | 2020-03-16 | 2022-09-01 | Flash Therapeutics, Llc | Compounds for treating or inhibiting recurrence of acute myeloid leukemia |
-
2021
- 2021-06-08 EP EP21736837.2A patent/EP4161933A1/en active Pending
- 2021-06-08 JP JP2022575408A patent/JP2023528659A/ja active Pending
- 2021-06-08 KR KR1020237000263A patent/KR20230035311A/ko active Pending
- 2021-06-08 IL IL298849A patent/IL298849A/en unknown
- 2021-06-08 WO PCT/US2021/036398 patent/WO2021252488A1/en not_active Ceased
- 2021-06-08 BR BR112022025012A patent/BR112022025012A2/pt unknown
- 2021-06-08 US US18/001,064 patent/US20230203045A1/en active Pending
- 2021-06-08 AU AU2021289345A patent/AU2021289345A1/en active Pending
- 2021-06-08 TW TW110120796A patent/TWI908811B/zh active
- 2021-06-08 MX MX2022015495A patent/MX2022015495A/es unknown
- 2021-06-08 CN CN202180057370.7A patent/CN116075513A/zh active Pending
- 2021-06-08 CA CA3186041A patent/CA3186041A1/en active Pending
-
2022
- 2022-12-28 CO CONC2022/0019131A patent/CO2022019131A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CN116075513A (zh) | 2023-05-05 |
| US20230203045A1 (en) | 2023-06-29 |
| IL298849A (en) | 2023-02-01 |
| CO2022019131A2 (es) | 2023-03-07 |
| KR20230035311A (ko) | 2023-03-13 |
| WO2021252488A1 (en) | 2021-12-16 |
| CA3186041A1 (en) | 2021-12-16 |
| JP2023528659A (ja) | 2023-07-05 |
| TW202208368A (zh) | 2022-03-01 |
| EP4161933A1 (en) | 2023-04-12 |
| AU2021289345A1 (en) | 2023-01-19 |
| MX2022015495A (es) | 2023-03-14 |
| TWI908811B (zh) | 2025-12-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112022022669A2 (pt) | Inibidores de nek7 quinase | |
| BR112023019435A2 (pt) | Inibidores de nek7 | |
| BR112022025012A2 (pt) | Inibidores de quinase de nek7 | |
| CO2026004076A2 (es) | Compuestos macrocíclicos, método de preparación de estos y uso de estos | |
| BR112021022796A2 (pt) | Inibidores de inflamassoma de nlrp3 | |
| BR112022008375A2 (pt) | Composto cíclico heterocíclico fundido substituído, método de preparação e uso farmacêutico deste | |
| AR122351A1 (es) | Derivados de metilquinazolinona como inhibidores de braf | |
| BR112022009563A2 (pt) | Compostos de pirrolotriazina atuando como inibidor de mnk | |
| MX385265B (es) | Derivados de 3-(((((2s-5r)-2-carbamoil-7-oxo-1,6-diazabiciclo [3.2.1]octan-6-il)oxi)sulfonil)oxi)-2,2-dimetilprop noato y compuestos relacionados como profarmacos oralmente administrados de inhibidores de beta-lactamasa para el tratamiento de infecciones bacterianas | |
| BR112021019256A2 (pt) | Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados | |
| BR112021023824A8 (pt) | Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica | |
| BR112021022536A2 (pt) | Derivado de fenilpropenilpiridina substituída e método de preparação do mesmo e uso médico do mesmo | |
| CO2024015820A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| BRPI0508540B8 (pt) | composto, composição farmacêutica, e, uso de um composto | |
| CO2024015816A2 (es) | Compuestos de heteroarilo para el tratamiento del dolor | |
| BR112016028642A2 (pt) | composto, composição farmacêutica, método de tratamento de uma doença ou condição, método de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase, método de inibição de reações imunes ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, e, uso de um composto, de um sal, de um isômero ou de uma mistura farmaceuticamente aceitável do mesmo. | |
| BR112016028814A2 (pt) | ?composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição de reações imunitárias ou crescimento excessivo ou destrutivo ou de proliferação de células cancerosas, kit, composto, um sal, um isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, de um sal, de um isômero, ou de uma mistura farmaceuticamente aceitável do mesmo? | |
| BR112017019653A2 (pt) | derivados heteroaril bicíclicos fundidos tendo atividade como inibidores de phd | |
| BR112021011325A2 (pt) | Derivados de rapamicina | |
| BR112021025764A2 (pt) | Derivado de pirimidina que inibe o crescimento de células cancerígenas e uso medicinal do mesmo | |
| BR112021020297A2 (pt) | Compostos de hexa-hidro-1h-pirazino[1,2-a]pirazina para o tratamento de doença autoimune | |
| CL2024002379A1 (es) | Composición farmacéutica y que comprende derivados de difenildiazol métodos de uso | |
| BR112016029065A2 (pt) | ?composto, composição farmacêutica, e, uso de um composto? | |
| BR112022026275A2 (pt) | Piridina-1,5-dionas que exibem inibição de mnk e seus métodos de uso | |
| BRPI1008000A2 (pt) | composto, hidrobrometo, hidrocloreto, metanossulfonato, etano-1, 2-dissulfonato, inibidor de hsp90, agente para inibir a atividade de atpase de hsp90, agente para inibir a ligação de hsp90 em atp, medicamento, agente anticâncer, composição farmacêutica, método para tratar câncer, e, uso de um composto. |